Mobile phone interventions to improve health outcomes among patients with chronic diseases: an umbrella review and evidence synthesis from 34 meta-analyses

IF 23.8 1区医学 Q1 MEDICAL INFORMATICS

Lancet Digital Health Pub Date : 2024-09-26 DOI:10.1016/S2589-7500(24)00119-5

Shufang Sun PhD , Otto Simonsson PhD , Prof Stephen McGarvey PhD , John Torous MD , Simon B Goldberg PhD

{"title":"Mobile phone interventions to improve health outcomes among patients with chronic diseases: an umbrella review and evidence synthesis from 34 meta-analyses","authors":"Shufang Sun PhD , Otto Simonsson PhD , Prof Stephen McGarvey PhD , John Torous MD , Simon B Goldberg PhD","doi":"10.1016/S2589-7500(24)00119-5","DOIUrl":null,"url":null,"abstract":"<div><div>This umbrella review of 34 meta-analyses, representing 235 randomised controlled trials done across 52 countries and 48 957 participants and ten chronic conditions, aimed to evaluate evidence on the efficacy of mobile phone interventions for populations with chronic diseases. We evaluated the strengths of evidence via the Fusar-Poli and Radua methodology. Compared with usual care, mobile apps had convincing effects on glycated haemoglobin reduction among adults with type 2 diabetes (d=0·44). Highly suggestive effects were found for both text messages and apps on various outcomes, including medication adherence (among patients with HIV in sub-Saharan Africa and people with cardiovascular disease), glucose management in type 2 diabetes, and blood pressure reduction in hypertension. Many effects (42%) were non-significant. Various gaps were identified, such as a scarcity of reporting on moderators and publication bias by meta-analyses, little research in low-income and lower-middle-income countries, and little reporting on adverse events.</div></div>","PeriodicalId":48534,"journal":{"name":"Lancet Digital Health","volume":"6 11","pages":"Pages e857-e870"},"PeriodicalIF":23.8000,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Digital Health","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2589750024001195","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICAL INFORMATICS","Score":null,"Total":0}

引用次数: 0

Abstract

This umbrella review of 34 meta-analyses, representing 235 randomised controlled trials done across 52 countries and 48 957 participants and ten chronic conditions, aimed to evaluate evidence on the efficacy of mobile phone interventions for populations with chronic diseases. We evaluated the strengths of evidence via the Fusar-Poli and Radua methodology. Compared with usual care, mobile apps had convincing effects on glycated haemoglobin reduction among adults with type 2 diabetes (d=0·44). Highly suggestive effects were found for both text messages and apps on various outcomes, including medication adherence (among patients with HIV in sub-Saharan Africa and people with cardiovascular disease), glucose management in type 2 diabetes, and blood pressure reduction in hypertension. Many effects (42%) were non-significant. Various gaps were identified, such as a scarcity of reporting on moderators and publication bias by meta-analyses, little research in low-income and lower-middle-income countries, and little reporting on adverse events.

查看原文本刊更多论文

改善慢性病患者健康状况的手机干预措施：34 项元分析的总综述和证据综述。

本综述包括 34 项荟萃分析，涉及 52 个国家的 235 项随机对照试验、48 957 名参与者和 10 种慢性病，旨在评估手机干预对慢性病患者的疗效。我们通过 Fusar-Poli 和 Radua 方法评估了证据的优势。与常规护理相比，手机应用对降低成人 2 型糖尿病患者的糖化血红蛋白具有令人信服的效果（d=0-44）。短信和应用程序对各种结果都有高度提示性效果，包括坚持用药（撒哈拉以南非洲的艾滋病毒感染者和心血管疾病患者）、2 型糖尿病患者的血糖管理和高血压患者的血压降低。许多效果（42%）并不显著。研究还发现了许多不足之处，如缺乏关于调节因素和荟萃分析发表偏差的报告，对低收入和中低收入国家的研究很少，对不良事件的报告也很少。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Lancet Digital Health Multiple-

CiteScore

41.20

自引率

1.60%

发文量

232

审稿时长

13 weeks

期刊介绍： The Lancet Digital Health publishes important, innovative, and practice-changing research on any topic connected with digital technology in clinical medicine, public health, and global health. The journal’s open access content crosses subject boundaries, building bridges between health professionals and researchers.By bringing together the most important advances in this multidisciplinary field,The Lancet Digital Health is the most prominent publishing venue in digital health. We publish a range of content types including Articles,Review, Comment, and Correspondence, contributing to promoting digital technologies in health practice worldwide.